Last reviewed · How we verify
Alphagan P
At a glance
| Generic name | Alphagan P |
|---|---|
| Sponsor | Hermann Eye Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Aqueous Humor Dynamics and Brimonidine (EARLY_PHASE1)
- Effect of Lowering IOP in Glaucoma Suspects With HM (NA)
- Evaluation of Safety and Efficacy of PDP-716 (PHASE3)
- Brimonidine Tartrate for Pterygium Surgery (NA)
- Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN-T Eye Drops 0.15% and ALPHAGAN-P Eye Drops 0.15% in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center Trial (PHASE4)
- Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD) (PHASE1, PHASE2)
- Pilocarpine and Brimonidine in Patients With Monofocal Lenses (EARLY_PHASE1)
- Pre-Administration of Brimonidine in Intravitreal Anti-VEGF Therapy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alphagan P CI brief — competitive landscape report
- Alphagan P updates RSS · CI watch RSS
- Hermann Eye Center portfolio CI